• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AJMC® in the Press, August 2, 2024

News
Article

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

An article from Managed Healthcare Executive® referenced an article published on AJMC.com, the website of The American Journal of Managed Care® (AJMC®). The article, “Deuruxolitinib Demonstrates Efficacy, Tolerability in Patients With Moderate to Severe AA,” highlighted results from a poster presented at the 2024 American Academy of Dermatology Annual Meeting, which found that the Janus kinase inhibitor deuruxolitinib resulted in hair regrowth in patients with moderate to severe alopecia areata, with efficacy and tolerability.

An article from Pharmacy Times® referenced a resource published by AJMC’s sister site, The Center for Biosimilars®. The page, “The Center for Biosimilars: Biosimilars Approvals,” lists all 49 approved biosimilars in the US, including the name of each drug and the conditions it treats.

Related Videos
CK Wang, MD, COTA
Dr Pankit Vachhani
Screenshot of Ivo Abraham, PhD, RN, during a video interview
Merrill H. Stewart, MD
Dr John Mascarenhas
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Carla Nester, MD, MSA, FASN, Stead Family Children's Hospital
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.